, The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system, Nutr
On average, 1 in 2 users paused or stopped their medication within the first 4 months
The meta-analysis further broke down how common nausea is for the five FDA-approved GLP-1 drug types, and another study looked at tirzepatides rate: Dulaglutide: 5-29% Exenatide: 5-59% Liraglutide: 10-48% Lixisenatide: 16-40% Semaglutide: 8-58% Tirzepatide: 20.43% Youll notice that these percentages vary quite a bit
GLP-1 agonists are made by different brands
A., Hussein, L., & Paliy, O
It is important to note that there is no official clinical evidence suggesting that morning or night dosing provides superior glycaemic control or weight loss outcomes for most injectable GLP-1 preparations